FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	D.C.	20549	
asimigton,	D.O.	20040	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Sukhtian Faisal Ghiath</u>				2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]						(Che	elationship of eck all applica Director	able)	Persor	n(s) to Issue			
	`	First) HERAPEUTICS,	(Middle) INC.		3. Date of Earliest Transaction (Month/Day/Year) 07/17/2020						Officer (below)	give title		Other (specify below)			
(Street) MONMO JUNCTIO	ON N		08852 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line) 【 Form fil	loint/Group Filing (Check Applicable iled by One Reporting Person iled by More than One Reporting					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			2A. Deemed Execution Date. if any (Month/Day/Yea		Code (Ir 8)			Securities Acquired (A) sposed Of (D) (Instr. 3, 4		Securities Beneficia Owned Fo Reported Transaction	Securities Form Beneficially (D) of Owned Following (I) (Ir		Direct Ir ndirect B r. 4) O	. Nature of ndirect leneficial lwnership nstr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	L. Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, if any Cod		Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Securiti Underlying Derivative (Instr. 3 and		ies g Security	Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable		epiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$1.58	07/17/2020		A		135,000		(1)	07	7/17/2030	Common Stock	135,000	\$0.00	135,000	0	D	

Explanation of Responses:

1. The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Remarks:

/s/ Lawrence Kenyon, Attorney- 07/21/2020 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.